ES2011120A6 - Forma de dosificacion para tratar las enfermedades cardiovasculares. - Google Patents

Forma de dosificacion para tratar las enfermedades cardiovasculares.

Info

Publication number
ES2011120A6
ES2011120A6 ES8802980A ES8802980A ES2011120A6 ES 2011120 A6 ES2011120 A6 ES 2011120A6 ES 8802980 A ES8802980 A ES 8802980A ES 8802980 A ES8802980 A ES 8802980A ES 2011120 A6 ES2011120 A6 ES 2011120A6
Authority
ES
Spain
Prior art keywords
cardiovascular diseases
isradipine
dosage form
treating cardiovascular
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8802980A
Other languages
English (en)
Inventor
Atul Davdatt Ayer
David R Swanson
Anthony L Kuczynsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ES2011120A6 publication Critical patent/ES2011120A6/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

FORMA DE DOSIFICACION PARA TRATAR LAS ENFERMEDADES CARDIOVASCULARES. ESTA INVENCION DESCRIBE UN DISPOSITIVO OSMOTICO QUE INCLUYE UNA PRIMERA COMPOSICION Y UNA SEGUNDA COMPOSICION QUE CONTIENE EL BENEFICIOSO FARMACO ISRADIPINA EN LA PRIMERA COMPOSICION, QUE ES UTIL EN EL TRATAMIENTO DE LAS ENFERMEDADES CARDIOVASCULARES.
ES8802980A 1987-10-02 1988-09-30 Forma de dosificacion para tratar las enfermedades cardiovasculares. Expired ES2011120A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/104,006 US4816263A (en) 1987-10-02 1987-10-02 Dosage form for treating cardiovascular diseases comprising isradipine

Publications (1)

Publication Number Publication Date
ES2011120A6 true ES2011120A6 (es) 1989-12-16

Family

ID=22298196

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8802980A Expired ES2011120A6 (es) 1987-10-02 1988-09-30 Forma de dosificacion para tratar las enfermedades cardiovasculares.

Country Status (22)

Country Link
US (1) US4816263A (es)
JP (1) JP2590235B2 (es)
KR (1) KR950010151B1 (es)
AT (1) AT402689B (es)
AU (1) AU615215B2 (es)
BE (1) BE1001101A5 (es)
CA (1) CA1317550C (es)
CH (1) CH677609A5 (es)
DE (1) DE3833282C2 (es)
DK (1) DK175564B1 (es)
ES (1) ES2011120A6 (es)
FI (1) FI92554C (es)
FR (1) FR2622798B1 (es)
GB (1) GB2210266B (es)
IE (1) IE61862B1 (es)
IT (1) IT1234215B (es)
LU (1) LU87351A1 (es)
NL (1) NL194748C (es)
NO (1) NO176466C (es)
PT (1) PT88618B (es)
SE (1) SE503471C2 (es)
ZA (1) ZA887362B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
WO2002100344A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100347A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
MXPA05010515A (es) * 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
KR101140559B1 (ko) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
CA2537837A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
MXPA06003043A (es) * 2003-09-17 2006-05-31 Xenoport Inc Tratamiento o prevencion del sindrome piernas inquietas utilizando prodrogas de analogos gaba.
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
EP1811986B1 (en) * 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
WO2007002013A2 (en) * 2005-06-20 2007-01-04 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
WO2007140272A2 (en) 2006-05-26 2007-12-06 Pharmacofore, Inc. Controlled release of phenolic opioids
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20110060040A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
EP2621282B1 (en) 2010-09-28 2020-04-15 The Regents of The University of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
CN105030726A (zh) * 2015-08-30 2015-11-11 四川百利药业有限责任公司 一种伊拉地平胶囊的制备方法
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
CA2998708C (en) 2015-10-01 2019-09-03 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
JP7234130B2 (ja) 2017-03-17 2023-03-07 エリージウム セラピューティクス， インコーポレイテッド 過剰摂取および乱用に対して抵抗性のポリサブユニットオピオイドプロドラッグ

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
AU2152888A (en) * 1987-08-25 1989-03-02 Cerra Metal Works Pty. Ltd. Masonry tie
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine

Also Published As

Publication number Publication date
US4816263A (en) 1989-03-28
DK175564B1 (da) 2004-12-06
FR2622798A1 (fr) 1989-05-12
GB2210266A (en) 1989-06-07
FR2622798B1 (fr) 1993-10-15
FI884526L (fi) 1989-04-03
FI884526A0 (fi) 1988-09-30
FI92554C (fi) 1994-12-12
GB2210266B (en) 1991-07-24
JP2590235B2 (ja) 1997-03-12
JPH01113316A (ja) 1989-05-02
BE1001101A5 (fr) 1989-07-11
KR950010151B1 (ko) 1995-09-11
CH677609A5 (es) 1991-06-14
GB8822852D0 (en) 1988-11-02
DE3833282A1 (de) 1989-04-20
SE8803486D0 (sv) 1988-09-30
KR890006218A (ko) 1989-06-12
DK545088D0 (da) 1988-09-29
NO884259L (no) 1989-04-03
SE503471C2 (sv) 1996-06-24
IT1234215B (it) 1992-05-06
AU615215B2 (en) 1991-09-26
ATA242288A (de) 1996-12-15
PT88618B (pt) 1993-07-30
ZA887362B (en) 1989-06-28
FI92554B (fi) 1994-08-31
SE8803486L (sv) 1989-04-03
NL194748B (nl) 2002-10-01
NL8802401A (nl) 1989-05-01
NO176466C (no) 1995-04-12
AU2293888A (en) 1989-04-06
DE3833282C2 (de) 1997-02-13
IE882960L (en) 1989-04-02
AT402689B (de) 1997-07-25
NL194748C (nl) 2003-02-04
NO176466B (no) 1995-01-02
CA1317550C (en) 1993-05-11
IT8867880A0 (it) 1988-09-30
DK545088A (da) 1989-04-03
IE61862B1 (en) 1994-11-30
PT88618A (pt) 1989-07-31
NO884259D0 (no) 1988-09-27
LU87351A1 (fr) 1989-04-06

Similar Documents

Publication Publication Date Title
ES2011120A6 (es) Forma de dosificacion para tratar las enfermedades cardiovasculares.
AR021535A1 (es) Formas de dosificacion de liberacion controlada que comprenden zolpidem o sales del mismo
ES2081857T3 (es) Nuevos inhibidores de alpha-glucosidasa.
ATE234090T1 (de) Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
ES2137372T3 (es) Solucion antifungica para las uñas.
CO4770978A1 (es) Empleo de epinastina para el tratamiento de dolores
PT95343A (pt) Processo para a preparacao de composicoes farmaceuticas contendo doses baixas de um agente anticoagulante oral tal como o warfarin e de um inibidor de plaquetas tal como o acido acetilsalilico,como ingredientes acticovos apropriadas para otratamento e/ou prevencao de doencas cardiacas
AR015257A1 (es) UNA COMPOSICION ACIDIFICADA Y EL USO DE DICHA COMPOSICION PARA LA MANUFACTURA DE UN MEDICAMENTO PARA EL TRATAMIENTO ToPICO DE CONDICIONES DE LAS UNAS Y DE LA PIEL
ES2160124T3 (es) Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades.
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
DE3650620D1 (de) Behandlungsverfahren kataboler dysfunktion
ES2061447T3 (es) Compuestos con efecto nootropo, agentes que los contienen y su empleo en el tratamiento y la profilaxis de disfunciones cognitivas.
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.
ATE201823T1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
ES2088877T3 (es) Procedimiento de preparacion del 3-pirrolidinol.
ES2059438T3 (es) Tioalquilamidas fenolicas inhibidoras de 5-lipoxigenasa.
KR910009267A (ko) 우울증의 치료방법
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.
ES2061561T3 (es) Tioeteres, sulfoxidos, y disulfuros fenolicos como inhibidores de 5-lipoxigenasa.
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
NO992985D0 (no) Anvendelse av COMT inhibitorer for fremstilling av et legemiddel til Õ forhindre diabetisk vaskulµr dysfunksjon
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2008-09-30

FD1A Patent lapsed

Effective date: 20081001